Mylan announces nationwide EpiPen recall over potential defect

Pfizer, the drug company that produces EpiPen auto-injectors, is voluntarily recalling two lots because they may have defective parts.

Generic drugmakerMylan said on Friday that its manufacturing partner for EpiPen devices had expanded a recall of the life-saving allergy shot in the United States and other markets.

Mylan said both reported failures included devices, manufactured between December 2015 and July 2016, that were already included in the original recall.

The company says the recall is being expanded as a precautionary measure.

In response, Mylan started offering $300 savings cards for patients who have to pay full price and began developing its generic spinoff.

EpiPen (0.3 mg epinephrine) auto-injector lot 5GU763, expiry date May 2017.

Mylan NV announced that the additional recalled items were part of 13 lots of EpiPen (0.3 mg) and EpiPen Jr.

Mylan advised consumers to use their current EpiPens, if needed, until they receive a replacement.

"There will be no additional replacement-related financial burden to [patients] as a result of this recall", Mylan said.

If you have one of the devices Health Canada encourages people to contact their pharmacy.

Epinephrine is the first-line treatment for a life-threatening allergic reaction (anaphylaxis) and access to this product is critical in the event of an emergency.